Literature DB >> 32467024

The association of Neurofibromatosis Type 1 and lower urinary tract dysfunction in the paediatric population - A critical review of literature.

Bruce Gao1, Keara DeCotiis2, Adam Bobrowski3, Martin Koyle2, Fardod O'Kelly2.   

Abstract

INTRODUCTION: Neurofibromatosis Type 1 (NF1) is an autosomal dominant, multisystem, neurocutaneous disorder. This condition has been associated with lower urinary tract dysfunction due to either direct genitourinary organ involvement or spinal cord compression. Based on current literature, there are no reviews examining the relationship between NF1 and lower urinary tract dysfunction (LUTD) in the paediatric population.
METHODS: A critical review of the literature was conducted using a systematic search of MEDLINE, PubMed and Embase yielding a total of 1285 manuscripts published up to 2019. Two independent reviewers selected studies for screening, eligibility and inclusion into the review. Following title, abstract and full-text review, 46 articles were analyzed.
RESULTS: Within these 46 articles, 79 cases were presented. The mean patient age at the time of presentation was 6.97 ± 9.19 years. The most common urologic presentations were irritative lower urinary tract symptoms (30%) and a newly discovered abdominopelvic mass (21%). Diagnostic investigations commonly demonstrated a retrovesical mass with direct invasion of the bladder in 58 cases (73%) and other genitourinary organ involvement in 39 cases (39%). Throughout the total case volume, LUTD was present in 49%. Pathology of malignancy was most commonly malignant peripheral nerve sheath tumour and rhabdomyosarcoma (20% and 14%, respectively). When indicated, surgical management of the lower urinary tract included both radical and partial cystectomy. Conservative management of urinary retention included clean intermittent catheterization (56%), suprapubic catheterization (22%), vesicostomy creation (11%) and mitrofanoff creation (11%).
CONCLUSION: A complete urologic evaluation including clinical, radiologic, and possibly pathologic investigation is warranted and should be performed for both diagnosis and appropriate management of LUTD in patients with NF1. Crown
Copyright © 2020. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bladder; LUTS; Neurofibromatosis; Pediatrics; Review; Urology

Mesh:

Year:  2020        PMID: 32467024     DOI: 10.1016/j.jpurol.2020.04.021

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  3 in total

1.  Scanning Imaging Study of Patients with Parkinson's Disease Lower Urinary Tract Dysfunction Based on Linear Equation.

Authors:  Yong Liu; Jiasheng Han; Xuguang Guo; Lei Fang; Ting Liu
Journal:  Scanning       Date:  2022-05-27       Impact factor: 1.750

2.  Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.

Authors:  Zhen-Duo Shi; Lin Hao; Xiao-Xiao Han; Zhuo-Xun Wu; Kun Pang; Yang Dong; Jia-Xin Qin; Guang-Yue Wang; Xuan-Ming Zhang; Tian Xia; Qing Liang; Yan Zhao; Rui Li; Shao-Qi Zhang; Jun-Hao Zhang; Jian-Gang Chen; Gong-Cheng Wang; Zhe-Sheng Chen; Cong-Hui Han
Journal:  Mol Cancer       Date:  2022-02-07       Impact factor: 27.401

3.  Pelvic plexiform neurofibroma during bowel/bladder dysfunction in an NF1 pediatric patient: A case report.

Authors:  Ricci Allen; Monica Epelman; Omar Cruz-Diaz; Pamela Ellsworth
Journal:  Urol Case Rep       Date:  2021-05-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.